<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>11093894</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Soriano, V</dc:author>
<dc:author>González-Lahoz, J</dc:author>
<dc:author>Barreiro, P</dc:author>
<dc:author>Dona, C</dc:author>
<dc:author>Jiménez-Náchera, I</dc:author>
<dc:description xml:lang="en">BACKGROUND Efavirenz (EFV) is one of the latest antiretroviral compounds appeared in the market. Its toxicity profile is not well known. PATIENTS AND METHODS The rate of adverse events was examined in 250 subjects enrolled in the expanded access program in a single institution located in Madrid, Spain. RESULTS Adverse events grade &gt;= 2 (WHO) were recorded in 33 (13.2%) persons. The most common were neuropsychiatric disorders (8.4%), cutaneous lesions (3.2%), and gastrointestinal problems (0.8%). The drug needed to be discontinued in 17 (6.8%) patients. CONCLUSION The rate of adverse events grade moderate-to-severe in patients receiving EFV is relatively low (13. 4%), without evidence of cross-toxicity (i.e., rash by nevirapine). Neuropsychiatric and dermatological conditions are the most common, and ten to resolve spontaneously in two</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2000 Sep 23 </dc:date>
<dc:title xml:lang="es">Toxicidad asociada a efavirenz en personas infectadas por el VIH incluidas en el programa de acceso expandido.</dc:title>
<dc:title xml:lang="en">[Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
